Testing version — LOERadar is in active testing. Features and data may change.

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE (AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN) | LOERadar

Viewing data from:

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

ANDA

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN | A200797 | LUPIN LTD

5 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: EXFORGE HCT(TE code: AB)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Novartis Pharmaceuticals Corporation v. Lupin Ltd. et al 1:2012cv00595 2 patentsANDA 200797amlodipine besylate/valsartan/hydrochlorothiazide	D. Del.	2012-05-14	Terminated 2012-11-06	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Products (5)

Sort:

#001 — EQ 5MG BASE;12.5MG;160MG

AB

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jun 3, 2015

No patent or exclusivity listings for this strength.

#002 — EQ 5MG BASE;25MG;160MG

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 3, 2015

#003 — EQ 10MG BASE;12.5MG;160MG

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 3, 2015

#004 — EQ 10MG BASE;25MG;160MG

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 3, 2015

#005 — EQ 10MG BASE;25MG;320MG

AB

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 3, 2015